A New FDA Approval, a Smarter Lithium, and Psilocybin in Phase 3 Made the First Quarter of 2026 One of the Most Active Periods for Bipolar Drug Development in Years

The first three months of 2026 delivered more meaningful movement in bipolar disorder treatment than a typical year: A new FDA approval, A novel approach to lithium delivery entering clinical trials, Psilocybin advancing to phase 3, and The psychiatric treatment pipeline is showing genuine momentum.

• The FDA approved Bysanti (milsaperidone) for acute manic and mixed episodes in bipolar I disorder. Developed by Vanda Pharmaceuticals, this new chemical in an atypical antipsychotic class. It demonstrated bioequivalence to iloperidone, which means it draws on more than 100,000 patient-years of real-world safety data. It is expected to be available in the US later this year.

• A second development targets one of the most common drugs in psychiatry: lithium. Alzamend Neuro announced the initiation of a phase 2 clinical trial of AL001. Its a novel lithium delivery system designed to provide lithium’s therapeutic benefits while reducing its toxicity. Lithium is one of the most effective treatments for bipolar mania, but it can cause kidney damage, thyroid problems, and other side effects. AL001 might be able to deliver lithium more precisely.

• The third notable advance involves psilocybin. COMP360, a synthetic psilocybin compound from COMPASS Pathways, reached phase 3 trials for treatment-resistant depression. The trial is not specifically focused on bipolar disorder. But clinicians who treat bipolar depression will watch closely. Earlier research suggests that psychedelics may ease bipolar depression without triggering mania.

• Other pipeline activity includes a drug. ProlivRX, an at-home neuromodulation device approved as a prescription for major depression. Several experimental compounds in earlier stages.

• Ketamine research for treatment-resistant bipolar depression continues to show promising response rates.

None of these is a cure unfortunately. The time it takes to get to regular patientse is always longer than we’d like. But for 46 million people worldwide with bipolar disorder, more options mean more chances to find a treatment that works.

Sources: Psychiatric Times, Psychiatric Times (Bysanti)

See recent or related posts:
• FDA Just Approved a New Drug for Bipolar I
• Ketamine for Treatment-Resistant Bipolar Depression
• Study: Psychedelics May Ease Bipolar Depression Without Sparking Mania
• AMPK Lithium Alternative for Treatment-Resistant Bipolar
• Practical Strategies for Managing Hypomania and Mania